Psychedelic Therapy Scrutinized by FDA Advisory Committee?

On June 4, the Food and Drug Administration (FDA) held a meeting of its Psychopharmacologic Drugs Advisory Committee. The FDA maintains 50 independent committees focused on different fields. Although not required to, it convenes these expert panels when facing difficult decisions.1 In this case, the...

Full description

Saved in:
Bibliographic Details
Published inJAMA : the journal of the American Medical Association Vol. 332; no. 12; pp. 963 - 964
Main Author Marks, Mason
Format Journal Article
LanguageEnglish
Published United States American Medical Association 24.09.2024
Subjects
Advisory Committees
Combined Modality Therapy - methods
Drug abuse
Drug Approval
Hallucinogens - therapeutic use
Humans
MDMA
Mental disorders
N-Methyl-3,4-methylenedioxyamphetamine - therapeutic use
Patient Selection
Post traumatic stress disorder
Psychedelic drugs
Psychological stress
Psychotherapy - methods
Randomized Controlled Trials as Topic
Stress Disorders, Post-Traumatic - therapy
United States
United States Food and Drug Administration
United States
Online AccessGet full text

Cover

More Information
Summary:On June 4, the Food and Drug Administration (FDA) held a meeting of its Psychopharmacologic Drugs Advisory Committee. The FDA maintains 50 independent committees focused on different fields. Although not required to, it convenes these expert panels when facing difficult decisions.1 In this case, the subject was 3,4-methylenedioxymethamphetamine (MDMA), a Schedule I controlled substance, which shows promise for treating posttraumatic stress disorder.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Editorial-2
ObjectType-Commentary-1
ObjectType-Article-3
ISSN:0098-7484
1538-3598
1538-3598
DOI:10.1001/jama.2024.13370